Fig. 4: Biocompatibility of the WTSA.
a Live-dead staining images of fibroblast cell (NIH-3T3) cultured with dissolution media with WTSA components, scale bar = 200 μm. b Cell viability rate of the WTSA components were evaluated using the CCK-8 assay (n = 3). c Representative H&E and MT-stained images of the skin layer where the WPPFM was implanted for 14 days, scale bar = 200 μm. d Immuno-fluorescent staining of macrophages and anti-inflammation (CD68; red, CD206; green) and apoptosis cell (caspase-3; red) images with DAPI (blue) of the cross-sectioned skin layer tissue where the WPPFM was implanted for 14 days, scale bar = 200 μm. e Representative H&E- and MT-stained images of cross-sectioned sciatic nerve which was wrapped with neural interface of WTSA for 14 days, scale bar = 200 μm. The width of the black dot lines indicates the fibrosis thickness. f Quantitative analysis of fibrosis layer thickness (n = 3). g Immuno-fluorescent staining of macrophages and anti-inflammation (CD68; red, CD206; green) and apoptosis cells (caspase-3; red) images with DAPI (blue) of the cross-sectioned sciatic nerve wrapped with neuronal interface of WTSA for 14 days, scale bar = 100 μm. h Quantitative analysis of expressed caspase-3 to DAPI ratio (n = 3). All error bars are presented as mean ± SD. P values were analyzed by one-way ANOVA with Tukey’s post hoc test. *P < 0.05, compared with that in the control group; #P < 0.05, compared with each group.
